Athma Dias: Limitations of PT and APTT in Predicting Thrombotic Risk
Athma Dias, Medical Laboratory Scientist at Teaching Hospital Ratnapura, shared a post on LinkedIn:
“The PT and APTT were never designed to predict thrombosis.
So why do we still rely on them as if they were?
A review published in February 2026 (MDPI, Biomolecules) makes something critically clear: while routine coagulation assays remain indispensable, they are fundamentally insensitive to hypercoagulable states and several emerging haemostasis biomarkers are now challenging the limits of what the coagulation laboratory can offer.
The core problem:
The Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) were designed to detect factor deficiencies causing Bleeding.
They screen only a fraction of the coagulation cascade under artificial conditions.
They tell us almost nothing about a patient’s actual thrombotic risk.
Yet thrombosis not bleeding is the leading cause of cardiovascular mortality globally.
Emerging global haemostasis assays are addressing this gap:
- Thrombin Generation Assay (TGA) measures the full kinetics of thrombin production and inhibition in plasma, capturing both pro- and anticoagulant balance in a single curve. Peak thrombin and endogenous thrombin potential (ETP) correlate with thrombotic and bleeding risk in ways the APTT cannot.
- Viscoelastic Testing (TEG/ROTEM) whole blood assays measuring clot formation, strength, and fibrinolysis in real time. Now guideline-recommended in major haemorrhage and cardiac surgery protocols.
- Thrombodynamics a novel spatial-temporal assay measuring clot growth from a surface-bound tissue factor activator, more closely mimicking in vivo vascular injury than any plasma-based assay.
- Neutrophil Extracellular Traps (NETs) emerging evidence published in Seminars in Thrombosis and Haemostasis (2026) confirms NETs as active participants in immunothrombosis, with NET biomarkers (citrullinated histone H3, cell-free DNA) showing promise as thrombotic risk markers in sepsis and cancer-associated thrombosis.
For the MLS in haemostasis, this evolution demands more than technical competency on the coagulation analyser.
It demands understanding haemostasis as a dynamic, spatially organised, cell-driven biological process not simply a cascade of clotting factors on a reagent strip.
Reference: Biomarkers of Coagulation Disorders MDPI Biomolecules, February 2026.
Is your laboratory using any global haemostasis assays beyond routine coagulation screening?”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause